BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 29108877)

  • 1. PIM kinases: From survival factors to regulators of cell motility.
    Santio NM; Koskinen PJ
    Int J Biochem Cell Biol; 2017 Dec; 93():74-85. PubMed ID: 29108877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pim Kinases Promote Migration and Metastatic Growth of Prostate Cancer Xenografts.
    Santio NM; Eerola SK; Paatero I; Yli-Kauhaluoma J; Anizon F; Moreau P; Tuomela J; Härkönen P; Koskinen PJ
    PLoS One; 2015; 10(6):e0130340. PubMed ID: 26075720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PIM kinase (and Akt) biology and signaling in tumors.
    Warfel NA; Kraft AS
    Pharmacol Ther; 2015 Jul; 151():41-9. PubMed ID: 25749412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pim-selective inhibitor DHPCC-9 reveals Pim kinases as potent stimulators of cancer cell migration and invasion.
    Santio NM; Vahakoski RL; Rainio EM; Sandholm JA; Virtanen SS; Prudhomme M; Anizon F; Moreau P; Koskinen PJ
    Mol Cancer; 2010 Oct; 9():279. PubMed ID: 20958956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and function of PIM kinases in osteosarcoma.
    Mou S; Wang G; Ding D; Yu D; Pei Y; Teng S; Fu Q
    Int J Oncol; 2016 Nov; 49(5):2116-2126. PubMed ID: 27826617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational Design of a Potent Pan-Pim Kinases Inhibitor with a Rhodanine-Benzoimidazole Structure.
    Sawaguchi Y; Yamazaki R; Nishiyama Y; Sasai T; Mae M; Abe A; Yaegashi T; Nishiyama H; Matsuzaki T
    Anticancer Res; 2017 Aug; 37(8):4051-4057. PubMed ID: 28739687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of regulators and inhibitors of Pim-1, a serine/threonine kinase, for tumour therapy (review).
    Liang C; Li YY
    Mol Med Rep; 2014 Jun; 9(6):2051-60. PubMed ID: 24737044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pim kinases in hematological malignancies: where are we now and where are we going?
    Mondello P; Cuzzocrea S; Mian M
    J Hematol Oncol; 2014 Dec; 7():95. PubMed ID: 25491234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting PIM Kinases to Overcome Therapeutic Resistance in Cancer.
    Toth RK; Warfel NA
    Mol Cancer Ther; 2021 Jan; 20(1):3-10. PubMed ID: 33303645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers.
    Brault L; Gasser C; Bracher F; Huber K; Knapp S; Schwaller J
    Haematologica; 2010 Jun; 95(6):1004-15. PubMed ID: 20145274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIM activity in tumours: A key node of therapy resistance.
    Rebello RJ; Huglo AV; Furic L
    Adv Biol Regul; 2018 Jan; 67():163-169. PubMed ID: 29111105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism-based combinations with Pim kinase inhibitors in cancer treatments.
    Yang Q; Chen LS; Gandhi V
    Curr Pharm Des; 2014; 20(42):6670-81. PubMed ID: 25341939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pim kinases in cancer: diagnostic, prognostic and treatment opportunities.
    Blanco-Aparicio C; Carnero A
    Biochem Pharmacol; 2013 Mar; 85(5):629-643. PubMed ID: 23041228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pim kinase isoforms: devils defending cancer cells from therapeutic and immune attacks.
    Jinesh GG; Mokkapati S; Zhu K; Morales EE
    Apoptosis; 2016 Nov; 21(11):1203-1213. PubMed ID: 27651368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin receptor substrate 1 is a substrate of the Pim protein kinases.
    Song JH; Padi SK; Luevano LA; Minden MD; DeAngelo DJ; Hardiman G; Ball LE; Warfel NA; Kraft AS
    Oncotarget; 2016 Apr; 7(15):20152-65. PubMed ID: 26956053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PIM kinases: an overview in tumors and recent advances in pancreatic cancer.
    Xu J; Zhang T; Wang T; You L; Zhao Y
    Future Oncol; 2014 Apr; 10(5):865-76. PubMed ID: 24799066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PIM1 accelerates prostate cancer cell motility by phosphorylating actin capping proteins.
    Santio NM; Vainio V; Hoikkala T; Mung KL; Lång M; Vahakoski R; Zdrojewska J; Coffey ET; Kremneva E; Rainio EM; Koskinen PJ
    Cell Commun Signal; 2020 Aug; 18(1):121. PubMed ID: 32771000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the Pim kinases in multiple myeloma.
    Keane NA; Reidy M; Natoni A; Raab MS; O'Dwyer M
    Blood Cancer J; 2015 Jul; 5(7):e325. PubMed ID: 26186558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The Pim family of protein kinases: structure, functions and roles in hematopoietic malignancies].
    Zhukova IuN; Alekseeva MG; Zakharevich NV; Shtil' AA; Danilenko VN
    Mol Biol (Mosk); 2011; 45(5):755-64. PubMed ID: 22393773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The PIM kinases in hematological cancers.
    Alvarado Y; Giles FJ; Swords RT
    Expert Rev Hematol; 2012 Feb; 5(1):81-96. PubMed ID: 22272708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.